• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2020 年 4 月 6 日，意大利伦巴第大区洛迪红区献血者中 SARS-CoV-2 特异性中和抗体的流行情况。

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.

机构信息

Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, Pavia, Italy.

Immunohematology and Transfusion Medicine Unit, Ospedale Maggiore di Lodi, Lodi, Italy.

出版信息

Euro Surveill. 2020 Jun;25(24). doi: 10.2807/1560-7917.ES.2020.25.24.2001031.

DOI:10.2807/1560-7917.ES.2020.25.24.2001031
PMID:32583766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7315724/
Abstract

We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 - when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19-70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.

摘要

我们评估了居住在意大利洛迪红区的献血者（BD）中的 SARS-CoV-2 RNA 和中和抗体。在 2020 年 2 月 20 日（伦巴第大区首例 COVID-19 病例确诊）之后招募的 390 名 BD 中，91 名（23%）年龄在 19-70 岁的人抗体呈阳性。另外 17 名（4.3%）BD 的病毒 RNA 检测呈阳性，因此约有 28%（108/390）的人有病毒暴露的证据。早在 2 月 12 日就采集的 5 份储存样本血清学呈阳性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/3a0ce1cd7c83/2001031-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/aa441d9357f6/2001031-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/3a0ce1cd7c83/2001031-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/aa441d9357f6/2001031-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/3a0ce1cd7c83/2001031-f2.jpg

相似文献

1
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.2020 年 4 月 6 日，意大利伦巴第大区洛迪红区献血者中 SARS-CoV-2 特异性中和抗体的流行情况。
Euro Surveill. 2020 Jun;25(24). doi: 10.2807/1560-7917.ES.2020.25.24.2001031.
2
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.恢复期血浆治疗严重急性呼吸综合征冠状病毒 2 型感染：2020 年 4 月 22 日至 5 月 12 日期间英国前 436 位供者的分析。
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2001260.
3
Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.恢复期血浆治疗 COVID-19：2020 年 4 月 22 日至 5 月 12 日，英国与高中和抗体水平相关的因素包括男性、年龄较大和住院。
Euro Surveill. 2020 Nov;25(45). doi: 10.2807/1560-7917.ES.2020.25.45.2001754.
4
A serological assay to detect SARS-CoV-2 seroconversion in humans.用于检测人类 SARS-CoV-2 血清转化的血清学检测方法。
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.
5
Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.伦巴第红区及周边伦巴第都会区和郊区献血者中 SARS-CoV-2 的血清流行率。
Clin Microbiol Infect. 2021 Jun;27(6):914.e1-914.e4. doi: 10.1016/j.cmi.2021.01.030. Epub 2021 Mar 4.
6
Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.检测 SARS-CoV-2 的中和抗体以确定 2020 年 3 月至 5 月间苏格兰献血人群的暴露情况。
Euro Surveill. 2020 Oct;25(42). doi: 10.2807/1560-7917.ES.2020.25.42.2000685.
7
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.新墨西哥州恢复期血浆和接受者中严重急性呼吸综合征冠状病毒 2 中和抗体滴度：2019 年冠状病毒病患者的开放性治疗研究。
J Infect Dis. 2020 Oct 13;222(10):1620-1628. doi: 10.1093/infdis/jiaa505.
8
Antibody-based therapies for COVID-19: Can Europe move faster?针对 COVID-19 的抗体疗法：欧洲能否行动更快？
PLoS Med. 2020 May 5;17(5):e1003127. doi: 10.1371/journal.pmed.1003127. eCollection 2020 May.
9
COVID-19: Main therapeutic options.新型冠状病毒肺炎：主要治疗选择
Tunis Med. 2020 Apr;98(4):299-303.
10
Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic.新冠疫情期间德国献血者中严重急性呼吸综合征冠状病毒2特异性抗体的流行情况。
Clin Lab. 2020 Oct 1;66(10). doi: 10.7754/Clin.Lab.2020.200915.

引用本文的文献

1
The Long-Term Immunity of a Microneedle Array Patch of a SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice.γ射线辐照的SARS-CoV-2 S1蛋白亚单位疫苗微针阵列贴片在小鼠体内的长期免疫
Vaccines (Basel). 2025 Jan 18;13(1):86. doi: 10.3390/vaccines13010086.
2
Fourth dose of microneedle array patch of SARS-CoV-2 S1 protein subunit vaccine elicits robust long-lasting humoral responses in mice.第四剂微针贴片 SARS-CoV-2 S1 蛋白亚单位疫苗在小鼠中引发强烈的持久体液免疫应答。
Int Immunopharmacol. 2024 Mar 10;129:111569. doi: 10.1016/j.intimp.2024.111569. Epub 2024 Feb 9.
3
Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020.

本文引用的文献

1
Challenges of Convalescent Plasma Therapy on COVID-19.恢复期血浆疗法治疗新冠病毒肺炎面临的挑战
J Clin Virol. 2020 Jun;127:104358. doi: 10.1016/j.jcv.2020.104358. Epub 2020 Apr 10.
2
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.中国武汉 COVID-19 患者恢复期血浆治疗。
J Med Virol. 2020 Oct;92(10):1890-1901. doi: 10.1002/jmv.25882. Epub 2020 Jun 29.
3
COVID-19: Herd immunity and convalescent plasma transfer therapy.新型冠状病毒肺炎：群体免疫与恢复期血浆输注疗法
2020 年 1 月至 12 月，在世界卫生组织欧洲区域广泛推出疫苗接种计划之前，对 SARS-CoV-2 抗体血清流行率进行系统评价，并对证据进行评估。
BMJ Open. 2023 Nov 6;13(11):e064240. doi: 10.1136/bmjopen-2022-064240.
4
Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).医护人员中SARS-CoV-2抗体反应的流行率及风险因素（2020年6月至2021年11月）
Eur J Public Health. 2023 Oct 10;33(5):923-929. doi: 10.1093/eurpub/ckad093.
5
Overview of SARS-COV-2 infection at the Butantan Penitentiary Progression Center.SARS-CoV-2 在布坦坦监狱进展中心的感染概述。
Rev Saude Publica. 2023 May 26;57(suppl 1):10s. doi: 10.11606/s1518-8787.2023057004717. eCollection 2023.
6
A Pilot Study on Blood Components in COVID-19 Affected Subjects: A Correlation to UPR Signalling and ER-Stress.新冠病毒感染患者血液成分的初步研究：与未折叠蛋白反应信号传导及内质网应激的相关性
Indian J Clin Biochem. 2023 Jul;38(3):374-384. doi: 10.1007/s12291-023-01121-8. Epub 2023 Mar 9.
7
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.SARS-CoV-2 S1 亚单位加强疫苗在老年小鼠中引发强烈的体液免疫应答。
Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10.
8
Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.血清流行率和 SARS-CoV-2 在普通人群中的入侵：大流行第一年的范围综述。
PLoS One. 2023 Apr 19;18(4):e0269104. doi: 10.1371/journal.pone.0269104. eCollection 2023.
9
19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern.19n01，一种针对奥密克戎BA.1、BA.2、BA.4/5以及其他值得关注的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的广泛中和抗体。
iScience. 2023 Apr 21;26(4):106562. doi: 10.1016/j.isci.2023.106562. Epub 2023 Apr 1.
10
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.mRNA 疫苗接种三剂后对实体瘤患者引发的免疫应答持久性：一年随访。
Int J Mol Sci. 2023 Apr 4;24(7):6731. doi: 10.3390/ijms24076731.
J Med Virol. 2020 Sep;92(9):1380-1382. doi: 10.1002/jmv.25870. Epub 2020 Jul 11.
4
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.韩国两名急性呼吸窘迫综合征 COVID-19 患者使用恢复期血浆疗法。
J Korean Med Sci. 2020 Apr 13;35(14):e149. doi: 10.3346/jkms.2020.35.e149.
5
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
6
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
7
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?采集和评估恢复期血浆用于 COVID-19 治疗：为什么以及如何？
Vox Sang. 2020 Aug;115(6):488-494. doi: 10.1111/vox.12926. Epub 2020 May 3.
8
Coronavirus Disease 2019 (COVID-19) in Italy.意大利的2019冠状病毒病（COVID-19）。
JAMA. 2020 Apr 14;323(14):1335. doi: 10.1001/jama.2020.4344.
9
West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors.西尼罗河病毒还是乌舒图病毒？一组无症状献血者体液和细胞免疫应答的三年随访研究。
Viruses. 2020 Jan 29;12(2):157. doi: 10.3390/v12020157.
10
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.实时 RT-PCR 检测 2019 新型冠状病毒（2019-nCoV）
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045.